Aquatic Capital Management LLC Has $48.36 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Aquatic Capital Management cut its Thermo Fisher stake by 32.1% in Q3 and now holds 99,711 shares worth about $48.36 million, roughly 0.9% of its portfolio and the fund's 10th largest holding.
• Analyst sentiment is broadly positive: of 21 covering analysts there is 1 Strong Buy, 18 Buy and 2 Hold, yielding a consensus target of $633.68 and an average rating of "Moderate Buy."
• Thermo Fisher beat Q4 estimates (EPS $6.57 vs $6.45; revenue $12.22B), raised its quarterly dividend to $0.47, but insiders including the CEO sold shares in February–March.

Aquatic Capital Management LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 99,711 shares of the medical research company's stock after selling 47,211 shares during the period. Thermo Fisher Scientific comprises approximately 0.9% of Aquatic Capital Management LLC's portfolio, making the stock its 10th biggest holding. Aquatic Capital Management LLC's holdings in Thermo Fisher Scientific were worth $48,362,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Brighton Jones LLC increased its position in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. grew its stake in shares of Thermo Fisher Scientific by 21.3% in the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 32,288 shares of the medical research company's stock worth $13,090,000 after purchasing an additional 5,664 shares during the last quarter. Arcadia Investment Management Corp MI raised its position in Thermo Fisher Scientific by 3.7% during the 2nd quarter. Arcadia Investment Management Corp MI now owns 32,202 shares of the medical research company's stock valued at $13,057,000 after purchasing an additional 1,136 shares during the last quarter. Finally, Foundations Investment Advisors LLC lifted its holdings in Thermo Fisher Scientific by 15.4% in the 2nd quarter. Foundations Investment Advisors LLC now owns 1,269 shares of the medical research company's stock worth $514,000 after buying an additional 169 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TMO. UBS Group reissued a "neutral" rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Citigroup lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a report on Friday, January 30th. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an "overweight" rating in a report on Tuesday, December 2nd. Evercore reaffirmed an "outperform" rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $633.68.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president owned 20,752 shares in the company, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $463.99 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a market cap of $172.36 billion, a price-to-earnings ratio of 26.15, a price-to-earnings-growth ratio of 2.68 and a beta of 0.96. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $557.83 and a two-hundred day simple moving average of $548.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping analysts' consensus estimates of $6.45 by $0.12. The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company's revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.10 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.47 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific's payout ratio is 9.70%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.